Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets. New data showed durable hepatitis D virus ...

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver pathobiology are driving the rapid ...

Los Angeles / Hong Kong, June 16, 2025 – The BIG3 – the premier global 3-on-3 basketball league – and East Asia Super League (EASL) – the Champions League of Asian basketball – today announced the ...

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease affecting 1.5 billion people worldwide, this momentum is strongly reflected at ...

BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative ...

NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT) (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the ...

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in ...

CEBU CITY, Philippines — Members of the East Asia Super League (EASL) Future Champions Elite Cebu Team has been named for the ...

The phase 3 D-LIVR study is the largest clinical trial conducted to date in chronic hepatitis D and continues to generate new analyses to inform the program's path forward. Under the leadership of CEO ...

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 ...